virogin.comCrawled Nov 12, 2026
Clinical Trials Virogin is dedicated to bringing next-generation immuno-oncolytic therapeutics to the clinic through our robust pipeline. Expanded Access HSV-1 Backbone Therapy FEATURES Indication Region Registration Number Phase IND Approval Phase 1 Phase 2 *VG161 to be developed for the Greater China market in partnership with CNBG, a Sinopharm Subsidiary (Virogin Biotech retains worldwide rights […]
mRNA Platform mRNA based therapies: powerful tools to combat diseases Rapid Development in Response to a Pandemic The first human trial of an mRNA vaccine commenced only 67 days after confirming the initial COVID-19 case, setting a record for the quickest human vaccine development in history. Sparking a Global R&D Surge and Earning a Nobel […]
Oncolytic Virotherapy Oncolytic viruses (OVs) are designed to directly kill tumor cells and induce an anti-tumor immune response. However, the clinical benefit of existing OVs remains limited, due to the inability to improve overall survival for patients. Virogin aims to engineer the viral genome and improve its potency by enhancing replication efficiency and arming the […]
Pipeline Virogin is dedicated to bringing next-generation immuno-oncology therapeutics to the clinic through our robust pipeline. Oncolytic Virus (Attenuated & Non-attenuated Viral Backbone） Backbone ID# Indications PHASE Discovery IND-Enabling Phase I Phase II Phase III Commercial Virogin rights Attenuated Transcription & TranslationDual Regulation (TTDR) mRNA Vaccines and Therapeutics (Conventional mRNA & Self-amplifying RNA） ID# Potential Indications […]
April 16, 2025 Virogin Biotech, a clinical stage biotech company specializing in next-generation oncolytic viruses, today announced a landmark clinical collaboration with Akeso Inc. (9926.HK) to advance a multi‑center, open‑label Phase Ib/II study evaluating the combination of Virogin’s VG201 with Akeso’s breakthrough bispecific antibody Ivonescimab (AK112). This study targets advanced colorectal cancer liver metastasis (CRLM), […]
Vancouver, BC Canada, September 6 2024 The first-in-class oncolytic virus developed by Virogin Biotech Co., Ltd. (“Virogin Biotech”), and exclusively licensed to CNBG-Virogin (Shanghai) Co., Ltd. (“CNBG-Virogin “) for clinical development and commercialization in the China region, was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products […]
VANCOUVER, British Columbia, November 15, 2022 (Newswire.com) – Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating VG201, a first-in-class HSV Type I oncolytic virus product constructed based on a transcriptional and translational dual-regulated (TTDR) backbone developed by Virogin Biotech. It is designed […]
October 23 - 26, 2022
October 24 - 26, 2022
VANCOUVER, British Columbia, November 15, 2022 (Newswire.com) – Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating VG201, a first-in-class HSV Type I oncolytic virus product constructed based on a transcriptional and translational dual-regulated (TTDR) backbone developed by Virogin Biotech. It is designed […]
Current Opportunities JOBS IN CANADA CO-OP IN CANADA JOBS IN USA JOBS IN CHINA JOBS IN CANADA Apply Now CO-OP IN CANADA While we do not have any formal career openings at this time, please contact careers@virogin.com if you are interested in joining our team. To stay informed about future roles at Virogin, follow our […]
Careers Interested in a career at Virogin? Explore and apply to our current opportunities below. Company Culture Talent & Diversity Core Values Benefits & Well-being Career Development Join Virogin Co-op Students Current Opportunities Company Culture At Virogin, every day we strive to achieve incredible progress by working together to pursue our shared mission in developing […]
Chief Executive Officer
Chief Medical Officer
Our Team We are a company with over 50 employees and R&D facilities in Vancouver, Canada and Shanghai, China. ALL LAB LEADERSHIP ALL BIO BIO BIO BIO BIO LAB BIO BIO BIO BIO BIO LEADERSHIP BIO BIO BIO BIO BIO
About Us Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs. Highlights of Virogin • Savvy pre-clinical and clinical teams with >25 […]
Strategy & Milestones Our clinical strategy harnesses the unique capabilities ofoncolytic viruses for effective cancer treatment Our goal is to deliver clinical benefits to patients, such as halting the progression of cancer and enhancing survival rates. In addition to continuous innovation of our OV backbone, Virogin is reimagining and redesigning clinical trial strategies, pushing the […]
Our History Virogin Biotech was founded in 2015, with a vision to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of highest medical need. April 01, 2015 Virogin Biotech Canada established. April 30, 2015 Virogin Biotech Hong Kong established. August 10, 2015 Seed run financing finished. August 14, 2015 Shenzhen […]
Contact Us R&D and Headquarters, Canada +1 (604) 720-8981 R&D Hub, China Phone: +86 021-699 00611 General Inquiries contact@virogin.com Careers Canada & US: careers@virogin.com China: chinacareers@virogin.com Name Email Subject Message Δ Partnerships Virogin aims to bring impactful therapeutic candidates to early clinical proof-of-concept for licensing and is committed to expand its pipeline through strategic collaborations. […]
Creating impactful drugs for patients with the highest medical need. At Virogin, we are at the forefront of developing novel oncolytic virotherapies.
